The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Nicole E., Woodman, Morgan, DiSilvestro, Paul A., Ribeiro, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466102/
https://www.ncbi.nlm.nih.gov/pubmed/32756436
http://dx.doi.org/10.3390/cancers12082150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466102/
https://www.ncbi.nlm.nih.gov/pubmed/32756436
http://dx.doi.org/10.3390/cancers12082150

Ejemplares similares